REFERENCES
1. Halle BR, Johnson DB. Defining and targeting BRAF mutations in solid tumors. Curr Treat Options Oncol. 2021;22:30.
2. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22:153-83.
3. Zhong J, Yan W, Wang C, et al. BRAF inhibitor resistance in melanoma: mechanisms and alternative therapeutic strategies. Curr Treat Options Oncol. 2022;23:1503-21.
4. Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. Genes Dis. 2023;10:76-88.
5. Degirmenci U, Yap J, Sim YRM, Qin S, Hu J. Drug resistance in targeted cancer therapies with RAF inhibitors. Cancer Drug Resist. 2021;4:665-83.
6. Biersack B, Tahtamouni L, Höpfner M. Role and function of receptor tyrosine kinases in BRAF mutant cancers. Receptors. 2024;3:58-106.
7. Castellani G, Buccarelli M, Arasi MB, et al. BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers. 2023;15:4026.
8. Torres-Collado AX, Knott J, Jazirehi AR. Reversal of resistance in targeted therapy of metastatic melanoma: lessons learned from vemurafenib (BRAFV600E-specific inhibitor). Cancers. 2018;10:157.
9. Hanly A, Gibson F, Nocco S, Rogers S, Wu M, Alani RM. Drugging the epigenome: overcoming resistance to targeted and immunotherapies in melanoma. JID Innov. 2022;2:100090.
10. Zaib S, Rana N, Khan I. Histone modifications and their role in epigenetics of cancer. Curr Med Chem. 2022;29:2399-411.
11. Patel AB, He Y, Radhakrishnan I. Histone acetylation and deacetylation - mechanistic insights from structural biology. Gene. 2024;890:147798.
12. Peng L, Seto E. Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol. 2011;206:39-56.
13. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with ‘epigenetic’ drugs: an update. Mol Oncol. 2012;6:657-82.
14. Biersack B, Nitzsche B, Höpfner M. HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer. Cancer Drug Resist. 2022;5:64-79.
15. Biersack B, Nitzsche B, Höpfner M. Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: new chances for sophisticated drug design and treatment optimization. Semin Cell Dev Biol. 2024;154:286-94.
16. Yeon M, Kim Y, Jung HS, Jeoung D. Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma. Front Cell Dev Biol. 2020;8:486.
17. Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9:52.
18. Rushworth LK, Hindley AD, O'Neill E, Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol. 2006;26:2262-72.
19. Lovly CM, Dahlman KB, Fohn LE, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 2012;7:e35309.
20. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:67.
21. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103-19.
22. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37:3183-99.
23. Allen A, Qin ACR, Raj N, et al. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. PLoS One. 2019;14:e0217399.
24. Dai X, Zhang X, Yin Q, et al. Acetylation-dependent regulation of BRAF oncogenic function. Cell Rep. 2022;38:110250.
25. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14:455-67.
26. Garbe C, Eigentler TK. Vemurafenib. In: Martens UM, Editor. Small molecules in oncology. Cham: springer international publishing; 2018. pp. 77-89.
27. Bowyer S, Lee R, Fusi A, Lorigan P. Dabrafenib and its use in the treatment of metastatic melanoma. Melanoma Manag. 2015;2:199-208.
28. Rose AAN. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Drugs Today. 2019;55:247-64.
29. Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol. 2021;32:959-67.
30. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877-88.
31. Eriksen M, Pfeiffer P, Rohrberg KS, et al. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. BMC Cancer. 2022;22:1321.
32. Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 2019;20:961-71.
33. Namikawa K, Yamazaki N. Targeted therapy and immunotherapy for melanoma in Japan. Curr Treat Options Oncol. 2019;20:7.
34. Okimoto RA, Lin L, Olivas V, et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci USA. 2016;113:13456-61.
35. Kotani H, Adachi Y, Kitai H, et al. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene. 2018;37:1775-87.
36. Scardaci R, Berlinska E, Scaparone P, et al. Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node. Mol Oncol. 2024;18:1355-77.
37. Yin H, Tang Q, Xia H, Bi F. Targeting RAF dimers in RAS mutant tumors: from biology to clinic. Acta Pharm Sin B. 2024;14:1895-923.
38. Biterge B, Schneider R. Histone variants: key players of chromatin. Cell Tissue Res. 2014;356:457-66.
39. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21:381-95.
40. Wahi A, Manchanda N, Jain P, Jadhav HR. Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer. Bioorg Chem. 2023;140:106833.
41. Milazzo G, Mercatelli D, Di Muzio G, et al. Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes. 2020;11:556.
42. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther. 2010;10:935-54.
43. Shanmugam G, Rakshit S, Sarkar K. HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Transl Oncol. 2022;16:101312.
44. Hodgkinson K, El Abbar F, Dobranowski P, et al. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clin Nutr. 2023;42:61-75.
45. Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969-78.
46. Mazzio EA, Soliman KFA. Whole-transcriptomic profile of SK-MEL-3 melanoma cells treated with the histone deacetylase inhibitor: trichostatin A. Cancer Genomics Proteomics. 2018;15:349-64.
47. Mcclure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Elsevier; 2018. pp. 183-211.
48. Sun Y, Hong JH, Ning Z, et al. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front Pharmacol. 2022;13:932914.
49. Pojani E, Barlocco D. Selective inhibitors of histone deacetylase 10 (HDAC-10). Curr Med Chem. 2022;29:2306-21.
50. Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One. 2012;7:e45045.
51. Jenke R, Reßing N, Hansen FK, Aigner A, Büch T. Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives. Cancers. 2021;13:634.
52. Biersack B, Polat S, Höpfner M. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin Cancer Biol. 2022;83:472-86.
53. Li Y, Huang Y, Cheng H, et al. Discovery of BRAF/HDAC dual inhibitors suppressing proliferation of human colorectal cancer cells. Front Chem. 2022;10:910353.
54. Wu QJ, Zhang TN, Chen HH, et al. The sirtuin family in health and disease. Signal Transduct Target Ther. 2022;7:402.
55. Sauve AA, Youn DY. Sirtuins: NAD+-dependent deacetylase mechanism and regulation. Curr Opin Chem Biol. 2012;16:535-43.
56. Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators and inhibitors: promises, achievements, and challenges. Pharmacol Ther. 2018;188:140-54.
57. Süssmuth SD, Haider S, Landwehrmeyer GB, et al; PADDINGTON Consortium. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease. Br J Clin Pharmacol. 2015;79:465-76.
58. Amengual JE, Clark-Garvey S, Kalac M, et al. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood. 2013;122:2104-13.
59. Abaza A, Vasavada AM, Sadhu A, et al. A systematic review of apoptosis in correlation with cancer: should apoptosis be the ultimate target for cancer treatment? Cureus. 2022;14:e28496.
60. Tian X, Srinivasan PR, Tajiknia V, et al. Targeting apoptotic pathways for cancer therapy. J Clin Invest. 2024;134:e179570.
61. Sheridan C, Brumatti G, Martin SJ. Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem. 2008;283:22128-35.
62. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2:183-92.
63. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525-35.
64. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393-403.
65. Peng Z, Gillissen B, Richter A, Sinnberg T, Schlaak MS, Eberle J. Effective targeting of melanoma cells by combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors. Int J Mol Sci. 2024;25:3453.
66. Hartman ML, Koziej P, Kluszczyńska K, Czyz M. Pro-apoptotic activity of MCL-1 inhibitor in trametinib-resistant melanoma cells depends on their phenotypes and is modulated by reversible alterations induced by trametinib withdrawal. Cancers. 2023;15:4799.
67. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene. 2011;30:366-71.
68. Fratta E, Giurato G, Guerrieri R, et al. Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective. Cell Death Discov. 2023;9:202.
69. Leo L, Bodemeyer V, De Zio D. The complex role of autophagy in melanoma evolution: new perspectives from mouse models. Front Oncol. 2019;9:1506.
70. Liu X, Wu J, Qin H, Xu J. The role of autophagy in the resistance to BRAF inhibition in BRAF-mutated melanoma. Target Oncol. 2018;13:437-46.
71. Li S, Song Y, Quach C, et al. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019;10:1693.
72. Verykiou S, Alexander M, Edwards N, et al. Harnessing autophagy to overcome mitogen - activated protein kinase kinase inhibitor - induced resistance in metastatic melanoma. Br J Dermatol. 2019;180:346-56.
73. Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov. 2015;5:410-23.
74. Xue G, Kohler R, Tang F, et al. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget. 2017;8:69204-18.
75. Nyakas M, Fleten KG, Haugen MH, et al. AXL inhibition improves BRAF-targeted treatment in melanoma. Sci Rep. 2022;12:5076.
76. Li Z, Jiang K, Zhu X, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016;370:332-44.
77. Liguoro D, Frigerio R, Ortolano A, et al. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors. Cell Death Dis. 2024;15:208.
78. Peng J, Lin Z, Chen W, et al. Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance. Heliyon. 2023;9:e17714.
79. Lai F, Jin L, Gallagher S, Mijatov B, Zhang XD, Hersey P. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. Current challenges in personalized cancer medicine. Elsevier; 2012. pp. 27-43.
80. Maertens O, Kuzmickas R, Manchester HE, et al. MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1-mutant melanomas. Cancer Discov. 2019;9:526-45.
81. Karagiannis D, Rampias T. HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity. Cancers. 2021;13:3575.
82. Ding G, Liu HD, Huang Q, et al. HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity. FEBS Lett. 2013;587:880-6.
83. Celesia A, Franzò M, Di Liberto D, et al. Oncogenic BRAF and p53 interplay in melanoma cells and the effects of the HDAC inhibitor ITF2357 (Givinostat). Int J Mol Sci. 2023;24:9148.
84. Kim Y, Park H, Park D, et al. Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs. J Biol Chem. 2010;285:25957-68.
85. Trost B, Thiruvahindrapuram B, Chan AJS, et al. Genomic architecture of autism from comprehensive whole-genome sequence annotation. Cell. 2022;185:4409-27.e18.
86. Jonas O, Oudin MJ, Kosciuk T, et al. Parallel in vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities. Clin Cancer Res. 2016;22:6031-8.
87. Wang L, Leite de Oliveira R, Huijberts S, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell. 2018;173:1413-25.e14.
88. Embaby A, Huijberts SCFA, Wang L, et al. A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600-mutated melanoma. Clin Cancer Res. 2024;30:3157-66.
89. Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ. 2012;19:2029-39.
90. Gallagher SJ, Gunatilake D, Beaumont KA, et al. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Int J Cancer. 2018;142:1926-37.
91. Borst A, Haferkamp S, Grimm J, et al. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines. Cancer Lett. 2017;404:70-8.
92. Heinemann A, Cullinane C, De Paoli-Iseppi R, et al. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget. 2015;6:21507-21.
93. Ha SD, Lewin N, Li SSC, Kim SO. HDAC8 activates AKT through upregulating PLCB1 and suppressing DESC1 expression in MEK1/2 inhibition-resistant cells. Cells. 2021;10:1101.
94. Emmons MF, Faião-Flores F, Sharma R, et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Res. 2019;79:2947-61.
95. Wilmott JS, Colebatch AJ, Kakavand H, et al. Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Mod Pathol. 2015;28:884-94.
96. Kobayashi Y, Ohtsuki M, Murakami T, et al. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene. 2006;25:512-24.
97. Carson R, Celtikci B, Fenning C, et al. HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL. Clin Cancer Res. 2015;21:3230-40.
98. Cheng J, Yang H, Fang J, et al. Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation. Nat Commun. 2015;6:7023.
99. Reu FJ, Bae SI, Cherkassky L, et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol. 2006;24:3771-9.
100. Gassenmaier M, Rentschler M, Fehrenbacher B, et al. Expression of DNA methyltransferase 1 is a hallmark of melanoma, correlating with proliferation and response to B-Raf and mitogen-activated protein kinase inhibition in melanocytic tumors. Am J Pathol. 2020;190:2155-64.
101. Dent P, Booth L, Poklepovic A, Kirkwood JM. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022;35:66-77.
102. Lai F, Guo ST, Jin L, et al. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis. 2013;4:e655.
103. Biran A, Brownstein M, Haklai R, Kloog Y. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer. 2011;128:691-701.
104. Booth L, Roberts JL, Sander C, et al. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017;8:16367-86.
105. Booth L, West C, Von Hoff D, Kirkwood JM, Dent P. GZ17-6.02 interacts with [MEK1/2 and B-RAF inhibitors] to kill melanoma cells. Front Oncol. 2021;11:656453.
106. Ling H, Li Y, Peng C, Yang S, Seto E. HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression. NAR Cancer. 2024;6:zcae018.
107. Fan TM, Selting KA. Exploring the potential utility of pet dogs with cancer for studying radiation-induced immunogenic cell death strategies. Front Oncol. 2018;8:680.
108. Miao Y, Quinn TP. Advances in receptor-targeted radiolabeled peptides for melanoma imaging and therapy. J Nucl Med. 2021;62:313-8.
109. Li M, Liu D, Lee D, et al. Enhancing the efficacy of melanocortin 1 receptor-targeted radiotherapy by pharmacologically upregulating the receptor in metastatic melanoma. Mol Pharm. 2019;16:3904-15.
110. Cui Y, Miao Y, Cao L, et al. Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity. Nat Commun. 2023;14:5740.
111. Fu H, Cheng L, Jin Y, Cheng L, Liu M, Chen L. MAPK inhibitors enhance HDAC inhibitor-induced redifferentiation in papillary thyroid cancer cells harboring BRAFV600E: an in vitro study. Mol Ther Oncolytics. 2019;12:235-45.
112. Cheng W, Liu R, Zhu G, Wang H, Xing M. Robust thyroid gene expression and radioiodine uptake induced by simultaneous suppression of BRAF V600E and histone deacetylase in thyroid cancer cells. J Clin Endocrinol Metab. 2016;101:962-71.
113. Madorsky Rowdo FP, Barón A, Gallagher SJ, et al. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive longterm BRAF inhibition. Int J Oncol. 2020;56:1429-41.
114. Heijkants R, Willekens K, Schoonderwoerd M, et al. Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma. Oncotarget. 2018;9:6174-87.
115. Granieri L, Marocchi F, Melixetian M, et al. Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. Cell Rep. 2022;40:111396.
116. Woods DM, Sodré AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res. 2015;3:1375-85.
117. López-Cobo S, Pieper N, Campos-Silva C, et al. Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors. Oncoimmunology. 2018;7:e1392426.
118. Hegedűs L, Rittler D, Garay T, et al. HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line. Pathol Oncol Res. 2020;26:2523-35.
119. Woan KV, Lienlaf M, Perez-Villaroel P, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015;9:1447-57.
120. Knox T, Sahakian E, Banik D, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019;9:6136.
121. Noonepalle SKR, Gracia-Hernandez M, Aghdam N, et al. Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma. J Exp Clin Cancer Res. 2024;43:263.
122. Gracia-Hernandez M, Yende AS, Gajendran N, et al. Targeting HDAC6 improves anti-CD47 immunotherapy. J Exp Clin Cancer Res. 2024;43:60.
123. Noonepalle S, Shen S, Ptáček J, et al. Rational design of suprastat: a novel selective histone deacetylase 6 inhibitor with the ability to potentiate immunotherapy in melanoma models. J Med Chem. 2020;63:10246-62.
124. Tavares MT, Shen S, Knox T, et al. Synthesis and pharmacological evaluation of selective histone deacetylase 6 inhibitors in melanoma models. ACS Med Chem Lett. 2017;8:1031-6.
125. Shen S, Hadley M, Ustinova K, et al. Discovery of a new isoxazole-3-hydroxamate-based histone deacetylase 6 inhibitor ss-208 with antitumor activity in syngeneic melanoma mouse models. J Med Chem. 2019;62:8557-77.
126. Kovalovsky D, Noonepalle S, Suresh M, et al. The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy. Sci Adv. 2024;10:eadp3687.
127. Peng X, Li L, Chen J, et al. Discovery of novel histone deacetylase 6 (HDAC6) inhibitors with enhanced antitumor immunity of anti-PD-L1 immunotherapy in melanoma. J Med Chem. 2022;65:2434-57.
128. Tsimberidou AM, Beer PA, Cartwright CA, et al. Preclinical development and First-in-Human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors. Clin Cancer Res. 2021;27:3584-94.
129. Bajpe PK, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R, Bernards R. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene. 2015;34:531-6.
130. Ohanna M, Bonet C, Bille K, et al. SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget. 2014;5:2085-95.
131. George J, Nihal M, Singh CK, Ahmad N. 4’-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor, inhibits melanoma cell growth through mitochondrial metabolic reprogramming. Mol Carcinog. 2019;58:1876-85.
132. Chhabra G, Singh CK, Guzmán-Pérez G, Ndiaye MA, Iczkowski KA, Ahmad N. Antimelanoma effects of concomitant inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL mice. J Invest Dermatol. 2022;142:1145-57.e7.
133. Sun T, Jiao L, Wang Y, Yu Y, Ming L. SIRT1 induces epithelial-mesenchymal transition by promoting autophagic degradation of E-cadherin in melanoma cells. Cell Death Dis. 2018;9:136.
134. Kriegl L, Vieth M, Kirchner T, Menssen A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget. 2012;3:1182-93.
135. Brandl L, Kirstein N, Neumann J, et al. The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target. Med Oncol. 2018;36:5.
136. Brandl L, Zhang Y, Kirstein N, et al. Targeting c-MYC through interference with NAMPT and SIRT1 and their association to oncogenic drivers in murine serrated intestinal tumorigenesis. Neoplasia. 2019;21:974-88.
137. Garcia-Peterson LM, Li X. Trending topics of SIRT1 in tumorigenicity. Biochim Biophys Acta Gen Subj. 2021;1865:129952.
138. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66:9483-91.
139. Mehrabipour M, Nakhaei-Rad S, Dvorsky R, et al. SIRT4 as a novel interactor and candidate suppressor of C-RAF kinase in MAPK signaling. Life Sci Alliance. 2024;7:e202302507.
140. Giblin W, Bringman-Rodenbarger L, Guo AH, et al. The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. J Clin Invest. 2021;131:138926.
141. Moon H, Zhu J, White AC. Sirt5 is dispensable for BrafV600E -mediated cutaneous melanoma development and growth in vivo. Exp Dermatol. 2019;28:83-5.
142. Strub T, Ghiraldini FG, Carcamo S, et al. SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat Commun. 2018;9:3440.
143. Qu N, Hu JQ, Liu L, et al. SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl1 pathway. Int J Oncol. 2017;50:1683-92.
144. Wang L, Guo W, Ma J, et al. Aberrant SIRT6 expression contributes to melanoma growth: role of the autophagy paradox and IGF-AKT signaling. Autophagy. 2018;14:518-33.
145. Baran M, Miziak P, Stepulak A, Cybulski M. The role of Sirtuin 6 in the deacetylation of histone proteins as a factor in the progression of neoplastic disease. Int J Mol Sci. 2023;25:497.
146. Du J, Yi X, Guo S, et al. SIRT7 promotes mitochondrial biogenesis to render the adaptive resistance to MAPK inhibition in melanoma. Biochem Biophys Res Commun. 2024;722:150161.
147. Yi X, Wang H, Yang Y, et al. SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation. Signal Transduct Target Ther. 2023;8:107.
